Allied logo

Allied(OTC) ALID

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-100%
1 Month+0%
$0.00
+0.00%
+0.00Today
Allied last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-10
Allied stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-06
1 month+0%USD 0.002026-08-06
3 month+0%USD 0.002026-05-27
Year to date-99.8%USD 0.002025-12-29
1 year-99.99%USD 0.012025-09-08
3 year-100%USD 0.222023-09-11
5 year-100%USD 1.722021-09-10
Since inception-100%USD 1.442019-09-11

Allied Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$72.10K

Net Income (TTM)

-$10.88M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-573.15 (Low)

Price

$0.00

Volume

400

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

N/A

ALID News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Allied

Allied Corp. specializes in the research, development, and production of cannabinoid health solutions, primarily operating in the United States. The company markets a diverse portfolio of natural health products derived from hemp under various brands.

Products and Services
  • Offers a range of cannabinoid health solutions, including CBD tinctures and gummies
  • Features specialized skincare products under the "MaXXa" brand
  • Engaged in pharmaceutical development with experimental drug candidates for PTSD
Growth Outlook
  • Recent product launches have expanded market reach and brand recognition
  • Engagement in clinical trials positions the company for future pharmaceutical opportunities
  • Increasing consumer demand for natural health products supports long-term growth potential
Financial Highlights
  • Q4 2023 revenue of $2,471 reflects ongoing operational challenges
  • Net income for Q4 2023 was -$5,135,789, indicating significant losses
  • Cash at the end of Q4 2023 increased to $209,736, showing improved liquidity
Allied Corp. operates in the healthcare sector, focusing on cannabinoid-based products. The company has developed a variety of health solutions, including CBD-infused beverages and topical applications, catering to a growing market for natural health alternatives. The recent expansion into pharmaceutical development, particularly with drug candidates targeting PTSD, highlights Allied Corp.'s commitment to innovation and addressing critical health issues. Despite facing financial challenges, including significant net losses in recent quarters, the company has shown resilience by increasing its cash reserves. The recent revenue figures indicate ongoing operational hurdles, yet the potential for growth remains strong due to rising consumer interest in cannabinoid products and the company's strategic initiatives in clinical research. As Allied Corp. continues to navigate its financial landscape, its focus on product development and market expansion may position it favorably for future opportunities in the evolving health and wellness industry.
AI Generated • Sep 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

15

CEO

Calum Hughes, PhD

Website

allied.health

Headquarters

Kelowna, BC V1Y OC2, CA

ALID Financials

Key Financial Metrics (TTM)

Gross Margin

-2027.53%

Operating Margin

-14235.43%

Net Income Margin

-14807.58%

Return on Equity

261.44%

Return on Capital

N/A

Return on Assets

-517.30%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

115.50M

Volume

400

Avg. Volume

12.492

Financials (TTM)

Gross Profit

-$1.54M

Operating Income

-$7.56M

EBITDA

-$7.59M

Operating Cash Flow

-$1.96M

Capital Expenditure

-$87.80K

Free Cash Flow

-$2.04M

Cash & ST Invst.

$209.74K

Total Debt

$5.86M

Allied Performance Analysis

Allied annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31USD 165,596N/A
20232023-08-31USD 72,096-56.5%
20242024-08-31USD 96,18033.4%
Allied sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-11-30-40.2%
Q22023-02-28-100.0%
Q32023-05-31N/A
Q42023-08-31N/A
Allied annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31USD -0.17N/A
20232023-08-31USD -0.11-34.6%
20242024-08-31USD -0.04-65.9%
Allied sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-11-30-52.4%
Q22023-02-28-35.7%
Q32023-05-31-4.7%
Q42023-08-31-138.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$2.47K

-97.9%

Gross Profit

-$1.51M

-2355.4%

Gross Margin

-609.24%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.67

N/A

Employees

150

N/A

Net Income

-$5.14M

-520.0%

EBITDA

-$2.29M

-106.2%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$209.74K

+118.4%

Total Debt

$5.86M

+15.4%

Accounts Receivable

$134.48K

+10.8%

Inventory

$107.51K

-89.2%

Long Term Debt

$98.56K

-40.1%

Short Term Debt

$5.76M

+17.2%

Return on Assets

-5.17%

N/A

Return on Invested Capital

1.51%

N/A

Free Cash Flow

$51.10K

+105.1%

Operating Cash Flow

$53.36K

+105.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SRUTFSproutly Canada Inc.
$0.00+0.00%
PHBIPharmagreen Biotech Inc.
$1.17+0.00%
CBDYTarget Group Inc.
$0.00+0.00%
MJNAMedical Marijuana, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About ALID

What is the current price of Allied?

Allied is trading at $0.00 per share.

What is the 52-week range for Allied?

Over the past 52 weeks, Allied has traded between $0.00 and $0.01.

How much debt does Allied have?

As of the most recent reporting period, Allied reported total debt of $6.61M.

How much cash does Allied have on hand?

Allied reported $359.10K in cash and cash equivalents in its most recent financial results.

What is Allied’s dividend yield?

Allied does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services